title: High viral fitness during acute HIV-1 infection.
abstract: Several clinical studies have shown that, relative to disease progression, HIV-1 isolates that are less fit are also less pathogenic. The aim of the present study was to investigate the relationship between viral fitness and control of viral load (VL) in acute and early HIV-1 infection. Samples were obtained from subjects participating in two clinical studies. In the PULSE study, antiretroviral therapy (ART) was initiated before, or no later than six months following seroconversion. Subjects then underwent multiple structured treatment interruptions (STIs). The PHAEDRA study enrolled and monitored a cohort of individuals with documented evidence of primary infection. The subset chosen were individuals identified no later than 12 months following seroconversion to HIV-1, who were not receiving ART. The relative fitness of primary isolates obtained from study participants was investigated ex vivo. Viral DNA production was quantified using a novel real time PCR assay. Following intermittent ART, the fitness of isolates obtained from 5 of 6 PULSE subjects decreased over time. In contrast, in the absence of ART the fitness of paired isolates obtained from 7 of 9 PHAEDRA subjects increased over time. However, viral fitness did not correlate with plasma VL. Most unexpected was the high relative fitness of isolates obtained at Baseline from PULSE subjects, before initiating ART. It is widely thought that the fitness of strains present during the acute phase is low relative to strains present during chronic HIV-1 infection, due to the bottleneck imposed upon transmission. The results of this study provide evidence that the relative fitness of strains present during acute HIV-1 infection may be higher than previously thought. Furthermore, that viral fitness may represent an important clinical parameter to be considered when deciding whether to initiate ART during early HIV-1 infection.
authors.affiliation: National Serology Reference Laboratory, St Vincent's Institute, Melbourne, Victoria, Australia.
authors.forename: Alicia
authors.initials: A
authors.lastname: Arnott
authors.forename: Darren
authors.initials: D
authors.lastname: Jardine
authors.forename: Kim
authors.initials: K
authors.lastname: Wilson
authors.forename: Paul R
authors.initials: PR
authors.lastname: Gorry
authors.forename: Kate
authors.initials: K
authors.lastname: Merlin
authors.forename: Patricia
authors.initials: P
authors.lastname: Grey
authors.forename: Matthew G
authors.initials: MG
authors.lastname: Law
authors.forename: Elizabeth M
authors.initials: EM
authors.lastname: Dax
authors.forename: Anthony D
authors.initials: AD
authors.lastname: Kelleher
authors.forename: Don E
authors.initials: DE
authors.lastname: Smith
authors.forename: Dale A
authors.initials: DA
authors.lastname: McPhee
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use; D015331:Cohort Studies; D056084:Genetic Fitness; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology*; D006801:Humans; D019562:Viral Load / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents